Survival of small-cell lung cancer patients after surgery: A single-center retrospective cohort study

Abstract

This study summarized and analyzed the clinical characteristics and prognosis of small-cell lung cancer (SCLC) patients after surgical treatment. The clinical data of 130 patients (99 males and 31 females) with SCLC treated by surgery and confirmed by postoperative pathological examination at Peking Union Medical College Hospital from April 2004 to April 2019 were retrospectively analyzed. Clinical characteristics, surgery, pathological stage, and perioperative treatment were summarized. Kaplan–Meier survival curve and Cox regression analysis were performed. Pathological examination revealed that 36 (27.69%) patients had stage I SCLC, 22 (16.92%) patients had stage II SCLC, 65 (50.00%) patients had stage III SCLC, and 7 (5.39%) patients had stage IV SCLC. The overall median survival time was 50 months (95% confidence interval, 10.8–89.2 months). The median survival time of stage I, II, III and IV SCLC patients was 148, 42, 32, and 10 months, respectively. In patients who underwent surgical treatment, postoperative adjuvant therapy and tumor stage were independent prognostic factors for survival (p < 0.05).Lobectomy and lymph nodes resection combined with adjuvant therapy were cautiously recommended for stage I–IIIa SCLC patients.

Prognostic factors and nomogram for pulmonary resected high-grade neuroendocrine carcinomas: a 20-year single institutional real-world experience

“…National Comprehensive Cancer Network (NCCN) guidelines, in fact, do not recommend resecting advanced tumors as they do not benefit from surgery, [ 10 ] although some recent reports seem to disclose a significant improvement in survival in stage II and stage IIIA SCLC undergoing lung resection [ 31 ]. Previous studies conducted at our institution have also validated this observation [ 32 ]. Identifying prognostic factors is therefore critical to guide management.…”